In this highly-integrated and multi-disciplinary Center without Walls entitled ?Identifying genes and pathways that modulate tau toxicity in FTD?, we seek to discover novel genetic modifiers of tauopathy to provide unique insight into disease mechanisms, as well as support the development and validation of an innovative approach to measure tau burden in patients using plasma samples. Taking advantage of the genome sequencing data available from PSP patients, Project 1 will identify genetic variants that influence disease risk, and in collaboration with the Human Biology Validation Core determine how key variants are associated with tau burden. As a complementary but alternative approach to identify genetic modifiers, Project 2 will utilize the Collaborative Cross and Diversity Outbred mouse strains developed at Jax Labs to uncover genetic variants that determine sensitivity or resistance to AAV-induced tauopathy. Project 3 will investigate the hypothesis that assessment of plasma tau levels following the administration of anti-tau antibodies provides a sensitive and specific biomarker for tau aggregation in the brain, employing samples from both murine models of tauopathy as well as patients enrolled in ARTFL and LEFFTDS. Project 4 will construct a disease signature for FTD-tau and mine public databases and systems analyses to predict pharmacologic and/or genetic interventions to reverse the signature, as well as elucidate how genetic modifiers identified in Projects 1 and 2 impact tau metabolism and secretion. The four research projects will be supported by the Administrative Core (Core A), the Viral Production and Cloning Core (Core B), the Human Biology Validation Core (Core C), and the Data Coordination Core (Core D). We envision that at the conclusion of the funding period, we will have: (i) identified key genes that determine either sensitivity or resistance to tau-mediated neurodegeneration; (ii) developed a sensitive and specific blood-based biomarker for tau deposition in the brain; (iii) discovered novel therapeutic targets predicted to reverse the transcriptional signature that defines tau mutation carriers; and (iv) determined how tau mutations and genetic modifiers of tauopathy impact tau metabolism, protein homeostasis and cell viability. Therefore, our Center is uniquely poised to enable the identification of patient populations at risk, while simultaneously enhancing diagnostic capabilities and expanding therapeutic possibilities.

Public Health Relevance

Tauopathies represent a group of devastating neurodegenerative disorders clinically characterized by a range of motor, cognitive and behavioral symptoms. The overall goals of our Center are to: identify key genes that influence disease susceptibility and resistance to tau toxicity; develop a sensitive and specific blood-based biomarker of tauopathy; discover new therapies predicted to reverse a genetic signature characteristic of tauopathy; and determine how genes and mutations influence tau stability and cell viability. Therefore, our Center is uniquely poised to enable the identification of patient populations at risk, while simultaneously enhancing diagnostic capabilities and expanding therapeutic and biomarker possibilities.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54NS100693-02
Application #
9358363
Study Section
Special Emphasis Panel (ZNS1)
Program Officer
Sutherland, Margaret L
Project Start
2016-09-30
Project End
2021-06-30
Budget Start
2017-07-01
Budget End
2018-06-30
Support Year
2
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Mayo Clinic Jacksonville
Department
Type
DUNS #
153223151
City
Jacksonville
State
FL
Country
United States
Zip Code
32224
Eftekharzadeh, Bahareh; Daigle, J Gavin; Kapinos, Larisa E et al. (2018) Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer's Disease. Neuron 99:925-940.e7
Dickson, Dennis W (2018) Neuropathology of Parkinson disease. Parkinsonism Relat Disord 46 Suppl 1:S30-S33
Kang, Silvia S; Ebbert, Mark T W; Baker, Kelsey E et al. (2018) Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau. J Exp Med 215:2235-2245
Sanchez-Contreras, Monica Y; Kouri, Naomi; Cook, Casey N et al. (2018) Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci. Mol Neurodegener 13:37
Kasanuki, Koji; Ross, Owen A; DeTure, Michael A et al. (2018) Relationships between lewy and tau pathologies in 375 consecutive non-Alzheimer's olfactory bulbs. Mov Disord 33:333-334
Razquin, Cristina; Ortega-Cubero, Sara; Rojo-Bustamante, Estefania et al. (2018) Target-enriched sequencing of chromosome 17q21.31 in sporadic tauopathies reveals no candidate variants. Neurobiol Aging 66:177.e7-177.e10
Ogaki, Kotaro; Martens, Yuka A; Heckman, Michael G et al. (2018) Multiple system atrophy and apolipoprotein E. Mov Disord 33:647-650
Conway, Olivia J; Carrasquillo, Minerva M; Wang, Xue et al. (2018) ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans. Mol Neurodegener 13:53
Zhao, Na; Liu, Chia-Chen; Van Ingelgom, Alexandra J et al. (2018) APOE ?2 is associated with increased tau pathology in primary tauopathy. Nat Commun 9:4388
Koga, Shunsuke; Kouri, Naomi; Walton, Ronald L et al. (2018) Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. Acta Neuropathol :

Showing the most recent 10 out of 15 publications